"It is estimated that 24-30% of the global population has Non-Alcoholic Fatty Liver Disease (NAFLD)1, which equates to 1.8 - 2.3 billion people. Of these, it is estimated that 20%, or up to 468 million people, will also develop non-alcoholic steatohepatitis (NASH), the most severe form of NAFLD where inflammation can cause liver damage and fibrosis. "
This is going to be big. RHT's current tech only used for a fairly rare disease. This new tech will be used on hundreds of millions of people.
I expect a major rerate.
"It is estimated that 24-30% of the global population has...
-
- There are more pages in this discussion • 167 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
